Identification of monoamine oxidase and cytochrome P450 isoenzymes involved in the deamination of phenethylamine-derived designer drugs (2C-series)

Biochemical Pharmacology

Volumn 73, Issue 2, 2007, Pages 287-297

  Theobald, Denis S ^a   Maurer, Hans H ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

2C series; Cytochrome P450; Designer drug; Metabolism; Monoamine oxidase

Indexed keywords

2,5 DIMETHOXY 4 METHYL BETA PHENETHYLAMINE; 2,5 DIMETHOXY 4 PROPYLTHIO BETA PHENETHYLAMINE; 4 BROMO 2,5 DIMETHOXY BETA PHENETHYLAMINE; 4 ETHYL 2,5 DIMETHOXY BETA PHENETHYLAMINE; 4 ETHYLTHIO 2,5 DIMETHOXY BETA PHENETHYLAMINE; 4 IODO 2,5 DIMETHOXY BETA PHENETHYLAMINE; ALDEHYDE; AMINE OXIDASE (FLAVIN CONTAINING); AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; COMPLEMENTARY DNA; CYTOCHROME P450 ISOENZYME; DESIGNER DRUG; ISOENZYME; PHENETHYLAMINE DERIVATIVE;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DEAMINATION; DNA EXTRACTION; EXTRACTION; GAS CHROMATOGRAPHY; MASS SPECTROMETRY; METABOLISM; METABOLITE; MICHAELIS MENTEN KINETICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

CYTOCHROME P-450 ENZYME SYSTEM; DEAMINATION; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; ISOENZYMES; KINETICS; MONOAMINE OXIDASE; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION;

EID: 33845191282     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2006.09.022     Document Type: Article

References (60)

1. Shulgin A., and Pihkal A. Chemical love story (1991), Transform Press, Berkley (CA)
2. Shulgin A. #142 PEA; phenethylamine. In: Dan J., and Pihkal A. (Eds). Chemical love story (1991), Transform Press, Berkley (CA) 815-818
3. de Boer D., and Bosman I. A new trend in drugs-of-abuse; the 2C-series of phenethylamine designer drugs. Pharm World Sci 26 (2004) 110-113
4. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Report on the risk assessment of 2C-I, 2C-T-2 and 2C-T-7 in the framework of the joint action on new synthetic drugs. http://www.emcdda.eu.int/multimedia/publications/risk_assessments/2Cs_2003_1636.pdf, 2004.
5. Schifano F., Deluca P., Agosti L., Martinotti G., Corkery J.M., Alex B., et al. New trends in the cyber and street market of recreational drugs? The case of 2C-T-7 ('Blue Mystic'). J Psychopharmacol 19 (2005) 675-679
6. Drug Enforcement Administration-Office of Forensic Sciences. BZP and Nexus tablets. Microgram 34 (2001) 3
7. Drug Enforcement Administration-Office of Forensic Sciences. 2,5-Dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7). Microgram 34 (2001) 193
8. Drug Enforcement Administration-Office of Forensic Sciences. Dipropyltryptamine and 2C-I in portland, oregon. Microgram 37 (2004) 113-114
9. Drug Enforcement Administration-Office of Forensic Sciences. 2C-I tablets in the Balearic Islands (spain). Microgram 37 (2004) 48-49
10. Drug Enforcement Administration-Office of Forensic Sciences. 2,5-Dimethoxy-4-ethylphenethylamine (2C-E) encountered in FT. Pierce, Florida and Royal Oak, Michigan. Microgram 37 (2004) 193-194
11. Drug Enforcement Administration-Office of Forensic Sciences. 2,5-Dimethoxy-4-ethylphenethylamine (2C-E) capsules in Bettendorf, Iowa. Microgram 38 (2005) 59
12. Drug Enforcement Administration - Department of Justice. Schedules of controlled substances; placement of 2,5-dimethoxy-4-(n)-propylthiophenethylamine and N-benzylpiperazine into schedule i of the controlled substances act. Fed Register 69 (2004) 12794-12797
13. European Communities. Council decision 2003/847/JHA of 27 November 2003 concerning control measures and criminal sanctions in respect of the new synthetic drugs 2C-I, 2C-T-2, 2C-T-7 and TMA-2. Off J Eur Commun 2003;L321:64-5.
14. WHO expert committee on drug dependence. Evaluation of dependence-producing drugs-32nd report of the WHO expert committee on drug dependence. EB 109/33, 2001.
15. Johnson M.P., Mathis C.A., Shulgin A.T., Hoffman A.J., and Nichols D.E. [125I]-2-(2,5-dimethoxy-4-iodophenyl)aminoethane ([125I]-2C-I) as a label for the 5-HT2 receptor in rat frontal cortex. Pharmacol Biochem Behav 35 (1990) 211-217
16. Glennon R.A., Raghupathi R., Bartyzel P., Teitler M., and Leonhardt S. Binding of phenylalkylamine derivatives at 5-HT1C and 5-HT2 serotonin receptors: evidence for a lack of selectivity. J Med Chem 35 (1992) 734-740
17. Glennon R.A., Titeler M., and Lyon R.A. A preliminary investigation of the psychoactive agent 4-bromo-2,5-dimethoxyphenethylamine: a potential drug of abuse. Pharmacol Biochem Behav 30 (1988) 597-601
18. Nichols D.E., Frescas S., Marona-Lewicka D., Huang X., Roth B.L., Gudelsky G.A., et al. 1-(2,5-Dimethoxy-4-(trifluoromethyl)phenyl)-2-aminopropane: a potent serotonin 5-HT2A/2C agonist. J Med Chem 37 (1994) 4346-4351
19. Cozzi N.V., and Nichols D.E. 5-HT2A receptor antagonists inhibit potassium-stimulated gamma-aminobutyric acid release in rat frontal cortex. Eur J Pharmacol 309 (1996) 25-31
20. Acuna-Castillo C., Villalobos C., Moya P.R., Saez P., Cassels B.K., and Huidobro-Toro J.P. Differences in potency and efficacy of a series of phenylisopropylamine/phenylethylamine pairs at 5-HT(2A) and 5-HT(2C) receptors. Br J Pharmacol 136 (2002) 510-519
21. Villalobos C.A., Bull P., Saez P., Cassels B.K., and Huidobro-Toro J.P. 4-Bromo-2,5-dimethoxyphenethylamine (2C-B) and structurally related phenylethylamines are potent 5-HT2A receptor antagonists in Xenopus laevis oocytes. Br J Pharmacol 141 (2004) 1167-1174
22. Khorana N., Pullagurla M.R., Dukat M., Young R., and Glennon R.A. Stimulus effects of three sulfur-containing psychoactive agents. Pharmacol Biochem Behav 78 (2004) 821-826
23. Fantegrossi W.E., Harrington A.W., Eckler J.R., Arshad S., Rabin R.A., Winter J.C., et al. Hallucinogen-like actions of 2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7) in mice and rats. Psychopharmacology (Berl) 181 (2005) 496-503
24. Lobos M., Borges Y., Gonzalez E., and Cassels B.K. The action of the psychoactive drug 2C-B on isolated rat thoracic aorta. Gen Pharmacol 23 (1992) 1139-1142
25. Saez P., Borges Y., Gonzalez E., and Cassels B.K. Alpha-adrenergic and 5-HT2-serotonergic effects of some beta-phenylethylamines on isolated rat thoracic aorta. Gen Pharmacol 25 (1994) 211-216
26. Curtis B., Kemp P., Harty L., Choi C., and Christensen D. Postmortem identification and quantitation of 2,5-dimethoxy-4-n-propylthiophenethylamine using GC-MSD and GC-NPD. J Anal Toxicol 27 (2003) 493-498
27. Theobald D.S., Fehn S., and Maurer H.H. New designer drug 2,5-dimethoxy-4-propylthiophenethylamine (2C-T-7): studies on its metabolism and toxicological detection in rat urine using gas chromatography/mass spectrometry. J Mass Spectrom 40 (2005) 105-116
28. Theobald D.S., Staack R.F., Puetz M., and Maurer H.H. New designer drug 2,5-dimethoxy-4-ethylthio-beta-phenethylamine (2C-T-2): studies on its metabolism and toxicological detection in rat urine using gas chromatography/mass spectrometry. J Mass Spectrom 40 (2005) 1157-1172
29. Theobald D.S., Puetz M., Schneider E., and Maurer H.H. New designer drug 4-iodo-2,5-dimethoxy-beta-phenethylamine (2C-I): studies on its metabolism and toxicological detection in rat urine using gas chromatographic/mass spectrometric and capillary electrophoretic/mass spectrometric techniques. J Mass Spectrom 41 (2006) 872-886
30. Theobald D.S., and Maurer H.H. Studies on the metabolism and toxicological detection of the designer drug 4-ethyl-2,5-dimethoxy-β-phenethylamine (2C-E) in rat urine using gas chromatographic-mass spectrometric techniques. J Chromatogr B: Anal Technol Biomed Life Sci (2006) [Epub ahead of print]
31. Theobald D.S., and Maurer H.H. Studies on the metabolism and toxicological detection of the designer drug 2,5-dimethoxy-4-methyl-β-phenethylamine (2C-D) in rat urine using gaschromatographic-massspectrometric techniques. J Mass Spectrom (2006) in revision
32. Kanamori T., Inoue H., Iwata Y., Ohmae Y., and Kishi T. In vivo metabolism of 4-bromo-2,5-dimethoxyphenethylamine (2C-B) in the rat: identification of urinary metabolites. J Anal Toxicol 26 (2002) 61-66
33. Kanamori T., Tsujikawa K., Ohmae Y., Iwata Y., Inoue H., Inouye Y., et al. Excretory profile of 4-bromo-2,5-dimethoxy-phenethylamine (2C-B) in rat. J Health Sci 49 (2003) 166-169
34. de Boer D., dos Reys L.A., Pylon N., Gijzels M., Bosman I.J., and Maes R.A.A. Preliminary results on the urinary excretion of 2C-B (4-bromo-2,5-dimethoxyphenethylamine) and its metabolites In humans. Br J Pharmacol 127 (1999) 41P
35. Carmo H., Boer D., Remiao F., Carvalho F., Reys L.A., and Bastos M.L. Metabolism of the designer drug 4-bromo-2,5-dimethoxyphenethylamine (2C-B) in mice, after acute administration. J Chromatogr B: Anal Technol Biomed Life Sci 811 (2004) 143-152
36. Carmo H., Hengstler J.G., de Boer D., Ringel M., Remiao F., Carvalho F., et al. Metabolic pathways of 4-bromo-2,5-dimethoxyphenethylamine (2C-B): analysis of phase I metabolism with hepatocytes of six species including human. Toxicology 206 (2005) 75-89
37. Kanamori T., Tsujikawa K., Ohmae Y., Iwata Y.T., Inoue H., Kishi T., et al. A study of the metabolism of methamphetamine and 4-bromo-2,5-dimethoxyphenethylamine (2C-B) in isolated rat hepatocytes. Forensic Sci Int 148 (2005) 131-137
38. Evans W.E., and McLeod H.L. Pharmacogenomics-drug disposition, drug targets, and side effects. N Engl J Med 348 (2003) 538-549
39. Howard L.A., Sellers E.M., and Tyndale R.F. The role of pharmacogenetically-variable cytochrome P450 enzymes in drug abuse and dependence. Pharmacogenomics 3 (2002) 185-199
40. Miller J.R., and Edmondson D.E. Structure-activity relationships in the oxidation of para-substituted benzylamine analogues by recombinant human liver monoamine oxidase A. Biochemistry 38 (1999) 13670-13683
41. Kalgutkar A.S., Dalvie D.K., Castagnoli Jr. N., and Taylor T.J. Interactions of nitrogen-containing xenobiotics with monoamine oxidase (MAO) isozymes A and B: SAR studies on MAO substrates and inhibitors. Chem Res Toxicol 14 (2001) 1139-1162
42. Ortiz-de-Montellano P.R., and de-Voss J.J. Substrate oxidation by cytochrome P450 enzymes. In: Ortiz-de-Montellano P.R. (Ed). Cytochrome P450-structure, mechanism, and biochemistry (2005), Kluwer Academic/Plenum Publishers, New York 183-245
43. Theobald D.S., Fehn S., and Maurer H.H. New designer drug 2,5-dimethoxy-4-propylthiophenethylamine (2C-T-7): studies on its metabolism in rat urine using GC/MS. Medimond (2005) 143-146 (Ed. Oesch F)
44. Theobald DS, Fritschi G, Maurer HH. Studies on the toxicological detection of the designer drug 4-bromo-2,5-dimethoxy-β-phenethylamine (2C-B) in rat urine using gaschromatography-massspectrometry. J Chromatogr B: Anal Technol Biomed Life Sci; 2006 September 13 [Epub ahead of print].
45. McLafferty F.W., and Turecek F. Interpretation of mass spectra (1993), University Science Books, Mill Valley, CA
46. Smith R.M., and Busch K.L. Understanding mass spectra-a basic approach (1999), Wiley, New York (NY)
47. Kraemer T., Pflugmann T., Bossmann M., Kneller N.M., Peters F.T., Paul L.D., et al. Fenproporex N-dealkylation to amphetamine-enantioselective in vitro studies in human liver microsomes as well as enantioselective in vivo studies in Wistar and Dark Agouti rats. Biochem Pharmacol 68 (2004) 947-957
48. Springer D., Paul L.D., Staack R.F., Kraemer T., and Maurer H.H. Identification of the cytochrome P450 enzymes involved in the metabolism of 4′-methyl-(alpha)-pyrrolidinopropiophenone, a novel scheduled designer drug, in human liver microsomes. Drug Metab Dispos 31 (2003) 979-982
49. Springer D., Staack R.F., Paul L.D., Kraemer T., and Maurer H.H. Identification of cytochrome P450 enzymes involved in the metabolism of 4'-methoxy-pyrrolidinopropiophenone (MOPPP), a designer drug, in human liver microsomes. Xenobiotica 33 (2003) 989-998
50. Springer D., Paul L.D., Staack R.F., Kraemer T., and Maurer H.H. Identification of cytochrome P450 enzymes involved in the metabolism of 3′,4′-methylenedioxy-α-pyrrolidinopropiophenone (MDPPP), a designer drug, in human liver microsomes. Xenobiotica 35 (2005) 227-237
51. Staack R.F., Theobald D.S., Paul L.D., Springer D., Kraemer T., and Maurer H.H. In vivo metabolism of the new designer drug 1-(4-methoxyphenyl)piperazine (MeOPP) in rat and identification of the human cytochrome P450 enzymes responsible for the major metabolic step. Xenobiotica 34 (2004) 179-192
52. Staack R.F., Paul L.D., Springer D., Kraemer T., and Maurer H.H. Cytochrome P450 dependent metabolism of the new designer drug 1-(3-trifluoromethylphenyl)piperazine (TFMPP). In vivo studies in Wistar and Dark Agouti rats as well as in vitro studies in human liver microsomes. Biochem Pharmacol 67 (2004) 235-244
53. Staack R.F., Theobald D.S., Paul L.D., Springer D., Kraemer T., and Maurer H.H. Identification of human cytochrome p450 2D6 as major enzyme involved in the o-demethylation of the designer drug p-methoxymethamphetamine. Drug Metab Dispos 32 (2004) 379-381
54. Staack R.F., and Maurer H.H. Metabolism of designer drugs of abuse [review]. Curr Drug Metab 6 (2005) 259-274
55. Yu A.M., Granvil C.P., Haining R.L., Krausz K.W., Corchero J., Kupfer A., et al. The relative contribution of monoamine oxidase and cytochrome p450 isozymes to the metabolic deamination of the trace amine tryptamine. J Pharmacol Exp Ther 304 (2003) 539-546
56. Clarke S.E. In vitro assessment of human cytochrome P450. Xenobiotica 28 (1998) 1167-1202
57. Nandigama R.K., and Edmondson D.E. Structure-activity relations in the oxidation of phenethylamine analogues by recombinant human liver monoamine oxidase A. Biochemistry 39 (2000) 15258-15265
58. Miller L.G., Friedman H., and Greenblatt D.J. Measurement of clonazepam by electron-capture gas-liquid chromatography with application to single-dose pharmacokinetics. J Anal Toxicol 11 (1987) 55-57
59. Green A.L., and El Hait M.A. p-Methoxyamphetamine, a potent reversible inhibitor of type-A monoamine oxidase in vitro and in vivo. J Pharm Pharmacol 32 (1980) 262-266
60. Scorza M.C., Carrau C., Silveira R., Zapata-Torres G., Cassels B.K., and Reyes-Parada M. Monoamine oxidase inhibitory properties of some methoxylated and alkylthio amphetamine derivatives: structure-activity relationships. Biochem Pharmacol 54 (1997) 1361-1369